Stay updated with breaking news from Development For Ipsen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Palovarotene is the first medicine to be submitted for regulatory approval for fibrodysplasia ossificans progressiva , an ultra-rare disease with an estimated prevalence of 1.36 per million... | May 26, 2023
Palovarotene is the first medicine to be submitted for regulatory approval for fibrodysplasia ossificans progressiva (FOP), an ultra-rare disease with an estimated prevalence of 1.36 per million individuals
Ipsen to request re-examination of CHMP opinion on palovarotene as a potential treatment for fibrodysplasia ossificans progressiva in E.U. FOP is an ultra-rare disease that continuously and
Onivyde treatment regimen significantly improved survival in a Phase III trial compared to nab-paclitaxel plus gemcitabine.
Investigational Onivyde (irinotecan liposome injection) in the NALIRIFOX treatment regimen demonstrated statistically significant improvements in overall survival and progression-free survival compared